Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 3/20 | 0.50 |
| ▸ | HTR2A | P28223 | 3/20 | 0.40 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.40 |
| ▸ | DPP4 | P27487 | 2/20 | 0.38 |
| ▸ | TRPA1 | O75762 | 2/20 | 0.38 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 1/20 | 0.38 |
| ▸ | HRH1 | P35367 | 2/20 | 0.37 |
| ▸ | MTOR | P42345 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GRM7 | Q14831 | 1/20 | 0.37 |
| ▸ | CES2 | O00748 | 1/20 | 0.36 |
| ▸ | CES1 | P23141 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31173889 | 0.86 | CHRNB2 (0.47) | TSHRTAAR1ALDH1A1LMNACYP3A4 | |
| SCHEMBL8110947 | 0.80 | TSHR (0.46) | TSHRHTR2ATAAR1DPP4TRPA1 | |
| SCHEMBL564025 | 0.79 | TSHR (0.50) | TSHRHTR2ATAAR1DPP4F2 | |
| SCHEMBL9425022 | 0.78 | TSHR (0.55) | TSHRHTR2ATAAR1DPP4TRPA1 | |
| SCHEMBL22042229 | 0.78 | TSHR (0.55) | TSHRHTR2ATAAR1DPP4F2 | |
| SCHEMBL28858478 | 0.77 | TSHR (0.48) | TSHRLMNACYP3A4 | |
| SCHEMBL28858569 | 0.77 | HTR2A (0.40) | HTR2AALDH1A1ALOX15 | |
| SCHEMBL8110499 | 0.77 | TSHR (0.42) | TSHRHTR2ATAAR1DPP4TRPA1 | |
| SCHEMBL138020 | 0.76 | TSHR (0.52) | TSHRHTR2ATAAR1DPP4F2 | |
| SCHEMBL31173879 | 0.75 | CHRNA7 (0.39) | TSHRALDH1A1RAB9ALMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1137788-A | Process for making polyphenols from ketones or aldehydes and phenols | DOW CHEMICAL CO (US) | 1996-12-11 | — | — | CN | claimed |
| EP-0725771-A1 | PROCESS FOR MAKING POLYPHENOLS FROM KETONES OR ALDEHYDES AND PHENOLS | THE DOW CHEMICAL COMPANY (US) | 1996-08-14 | — | — | EP | claimed |
| WO-1996006819-A1 | PROCESS FOR MAKING POLYPHENOLS FROM KETONES OR ALDEHYDES AND PHENOLS | THE DOW CHEMICAL COMPANY (US) | 1996-03-07 | — | — | WO | claimed |
| CN-119061410-A | Method for electrochemically synthesizing chlorobromide | 中国科学院大连化学物理研究所 | 2024-12-03 | — | — | CN | disclosed |
| CN-115197046-B | Halogenation method of unsaturated hydrocarbon | 华南理工大学 | 2023-12-15 | — | — | CN | disclosed |
| CN-115197046-A | Halogenation method of unsaturated hydrocarbon | 华南理工大学 | 2022-10-18 | — | — | CN | disclosed |
| US-20110313196-A1 | NOVEL PROCESS | HOFFMANN-LA ROCHE, INC. | 2011-12-22 | — | — | US | disclosed |
| CN-1856499-A | New 2-substituted, 4-amino-thiazolo[4,5-d] pyrimidines, useful as chemokine receptor antagonists, esp. cx3cr1 | ASTRAZENECA AB (SE) | 2006-11-01 | — | — | CN | disclosed |
| CN-1200105-A | Isomerization of bisphenols | DOW CHEMICAL CO (US) | 1998-11-25 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110313196-A1 | NOVEL PROCESS | CYP3A5, CYP3A4, GBA1 | TSHR 2563/4885HTR2A 1039/4885TAAR1 3928/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.